Ward:
>> You don't comprehend how strong the models were for this drug <<
I read the manuscripts, and I've worked with similar models. Don't know what more I could do to "comprehend".
>> When booking 90% plus GPM and growing revenues at 40%, funny but a significant portion falls to available cash. <<
Not enough to conduct multi-center phase III trials sufficient to target worldwide registration for multiple indications. That's what V1 was saying when you rudely indicated that he was wrong. You're talking, in the context of V1's point, about peanuts dropping to the bottom line. At the same time, you're representing us as uninformed.
>> It is quite obvious to me that you are not in tune with what is an exciting and strong trend being built by HMAF <<
It's "quite obvious" that you can't tolerate anyone who wants to present a balanced discussion, not even a MOGN bull. MOGN does not have, as V1 indicated, the resources required to take 114 forward alone. Calling "Bob" won't change that. If they attempt to do such, it is a clear indication that they could not license the product under reasonable terms and that competitive projects will move more rapidly through the clinic. The alternative, of course, would be a dilutive move, or a series of dilutive moves, to raise the needed cash.
>> You are incredibly mistaken if you think this company has a self-promotion problem. <<
I've never indicated that they do. I consider it a mistake to have discussed at 47% reduction of tumor burden in a release.
>> Blitzer knows MGI Pharma better than yourself......... you don't know what Chuck Blitzer knows. <<
True! But, what part of this statement didn't you understand.....
I still hold some MOGN
>> and yet you portray yourself as some type of
authority figure <<
I portray myself as someone who has judged the potential of this company accurately, and as someone who made the CORRECT call regarding Blitzer's '97 Europe BS.
Flash back to the summer of 1997. Blitzer had indicated that a european licensing deal was imminent. He also indicated that he would not give away any rights in North America and that support would be sufficient for worldwide development. Miljenko and I clearly said "no way". When he couldn't deliver on his promise, Blitzer didn't step up to say "I was full of it, let's go on.... the company is strong, and I have other options".
I'm glad that the company did have the option to continue alone. But, to address your criticism..... I challenged Blitzer on one point, and I was correct. I've now challenged you on one point (MOGN having sufficient resources to proceed alone with phase III), and I'm correct again. |
